The DOI matches its Crossref record; 76 of the 80 references it cites were found in a registry or an index.
Functional SARS-CoV-2-Specific Immune Memory Persists after Mild COVID-19
Open accessPublished version of a preprint
Abstract
The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) virus is causing a global pandemic, and cases continue to rise. Most infected individuals experience mildly symptomatic coronavirus disease 2019 (COVID-19), but it is unknown whether this can induce persistent immune memory that could contribute to immunity. We performed a longitudinal assessment of individuals recovered from mild COVID-19 to determine whether they develop and sustain multifaceted SARS-CoV-2-specific immunological memory. Recovered individuals developed SARS-CoV-2-specific immunoglobulin (IgG) antibodies, neutralizing plasma, and memory B and memory T cells that persisted for at least 3 months. Our data further reveal that SARS-CoV-2-specific IgG memory B cells increased over time. Additionally, SARS-CoV-2-specific memory lymphocytes exhibited characteristics associated with potent antiviral function: memory T cells secreted cytokines and expanded upon antigen re-encounter, whereas memory B cells expressed receptors capable of neutralizing virus when expressed as monoclonal antibodies. Therefore, mild COVID-19 elicits memory lymphocytes that persist and display functional hallmarks of antiviral immunity.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“Among cytokine profiles of spike-responsive memory T cells, production was dominated by the expression of IL-2 and IFN-γ that were highly expressed by CCR6− subsets.32, 33”
From Safety and immunogenicity of the SARS-CoV-2 ARCoV mRNA vaccine in Chinese adults: a randomised, double-blind, placebo-controlled, phase 1 trial (2022) · cites this paper as [33]
In the citing paper
“However, neutralizing antibody responses decay rapidly in early convalescence9,14–17.”
From Prospects for durable immune control of SARS-CoV-2 and prevention of reinfection (2021) · cites this paper as [9]
In the citing paper
“We and others have shown that SARS-CoV-2-specific memory B cells accumulate over the first few months after initial infection2,3,8,9,28 (Fig. 1a)”
From Prospects for durable immune control of SARS-CoV-2 and prevention of reinfection (2021) · cites this paper as [9]
In the citing paper
“The observations that frequencies of circulating memory B cells continue to increase for several months after recovery from COVID-19 (refs2,3,8,9,28), when most other responses are declining (Fig. 1a), suggest that recall of B cell memory may provide a mechanism to extend the duration of antibody-dependent protection in the face of waning serological titres.”
From Prospects for durable immune control of SARS-CoV-2 and prevention of reinfection (2021) · cites this paper as [9]
In the citing paper
“SARS-CoV-2 infection rapidly elicits nAbs (16, 21–24) that decline, but remain detectable, over several months (25–29).”
From mRNA vaccination boosts cross-variant neutralizing antibodies elicited by SARS-CoV-2 infection (2021) · cites this paper as [26]
In the citing paper
“SARS-CoV-2 infection can induce the production of neutralizing antibodies, and these antibodies are believed to contribute to protection from reinfection (Rodda et al., 2020; Wajnberg et al., 2020).”
From SARS-CoV-2 variants B.1.351 and P.1 escape from neutralizing antibodies (2021) · cites this paper as Rodda et al., 2020
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Hoffmann, M., Kleine-Weber, H., Schroeder, S., Krüger, N., Herrler, T., Erichsen, S., Schiergens, T. S., Herrler, G., Wu, N.-H., Nitsche, A., et al. (2020) · Cell · doi:10.1016/j.cell.2020.02.052 · Cited by 20,286
Wu, Z., & McGoogan, J. M. (2020) · JAMA · doi:10.1001/jama.2020.2648 · Cited by 17,016
Virological assessment of hospitalized patients with COVID-2019
Wölfel, R., Corman, V. M., Guggemos, W., Seilmaier, M., Zange, S., Müller, M. A., Niemeyer, D., Jones, T. C., Vollmar, P., Rothe, C., et al. (2020) · Nature · doi:10.1038/s41586-020-2196-x · Cited by 6,661
Two subsets of memory T lymphocytes with distinct homing potentials and effector functions
Sallusto, F., Lenig, D., Förster, R., Lipp, M., & Lanzavecchia, A. (1999) · Nature · doi:10.1038/44385 · Cited by 5,846 · cited 1×
“Antigen-specific memory CD4 T cells proliferate to re-seed the memory pool and generate effector cells upon antigen reexposure (Sallusto et al., 1999).”
Grifoni, A., Weiskopf, D., Ramirez, S. I., Mateus, J., Dan, J. M., Moderbacher, C. R., Rawlings, S. A., Sutherland, A., Premkumar, L., Jadi, R. S., et al. (2020) · Cell · doi:10.1016/j.cell.2020.05.015 · Cited by 3,595
Antibody responses to SARS-CoV-2 in patients with COVID-19
Long, Q.-X., Liu, B.-Z., Deng, H.-J., Wu, G.-C., Deng, K., Chen, Y.-K., Liao, P., Qiu, J.-F., Lin, Y., Cai, X.-F., et al. (2020) · Nature Medicine · doi:10.1038/s41591-020-0897-1 · Cited by 2,876
Self-citationSARS-CoV-2-specific T cell immunity in cases of COVID-19 and SARS, and uninfected controls
Le Bert, N., Tan, A. T., Kunasegaran, K., Tham, C. Y. L., Hafezi, M., Chia, A., Chng, M. H. Y., Lin, M., Tan, N., Linster, M., et al. (2020) · Nature · doi:10.1038/s41586-020-2550-z · Cited by 1,887
Convergent Antibody Responses to SARS-CoV-2 in Convalescent Individuals
Robbiani, D. F., Gaebler, C., Muecksch, F., Lorenzi, J. C. C., Wang, Z., Cho, A., Agudelo, M., Barnes, C. O., Gazumyan, A., Finkin, S., et al. (2020) · Nature · doi:10.1038/s41586-020-2456-9 · Cited by 1,853
Robust T Cell Immunity in Convalescent Individuals with Asymptomatic or Mild COVID-19
Sekine, T., Perez-Potti, A., Rivera-Ballesteros, O., Strålin, K., Gorin, J.-B., Olsson, A., Llewellyn-Lacey, S., Kamal, H., Bogdanovic, G., Muschiol, S., et al. (2020) · Cell · doi:10.1016/j.cell.2020.08.017 · Cited by 1,788
Immunological memory and protective immunity: understanding their relation
Ahmed, R., & Gray, D. (1996) · Science · doi:10.1126/science.272.5258.54 · Cited by 1,775 · cited 2×
“(legend continued on next page) ll Cell 184, 169–183, January 7, 2021 171 Article ll Article years, depending upon the specific viral infection (Slifka and Ahmed, 1996).”
Flagged first, then by citations
4 of the 80 references couldn’t be matched to a known paper.
Research works printed but not linked: 2
- Nellore, 2019, Fcrl5 and T-bet define influenza-specific memory B cells that predict long-lived antibody responses, bioRxiv
- Wajnberg, 2020, SARS-CoV-2 infection induces robust, neutralizing antibody responses that are stable for at least three months, medRxiv
Cited by
Sorted by citations
Items 301–400 of 644
Richardson, J. R., Götz, R., Mayr, V., Lohse, M. J., Holthoff, H., & Ungerer, M. (2022) · PLoS ONE · doi:10.1371/journal.pone.0266701 · Cited by 16
Xing, H., Zhu, L., Wang, P., Zhao, G., Zhou, Z., Yang, Y. A., Zou, H., & Yan, X. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.935573 · Cited by 16
Humoral immunity and B-cell memory in response to SARS-CoV-2 infection and vaccination
Fryer, H. A., Hartley, G. E., Edwards, E. S. J., O’Hehir, R. E., & van Zelm, M. C. (2022) · Biochemical Society Transactions · doi:10.1042/bst20220415 · Cited by 16
Clonal diversity predicts persistence of SARS-CoV-2 epitope-specific T-cell response
Zornikova, K. V., Khmelevskaya, A. A., Sheetikov, S. A., Kiryukhin, D. O., Shcherbakova, O. V., Titov, A., Zvyagin, I. V., & Efimov, G. A. (2022) · Communications Biology · doi:10.1038/s42003-022-04250-7 · Cited by 17
Longitudinal analysis of memory Tfh cells and antibody response following CoronaVac vaccination
Zhou, P., Cao, C., Ji, T., Zheng, T., Dai, Y., Liu, M., Jiang, J., Sun, D., Bai, Z., Lu, X., et al. (2023) · JCI Insight · doi:10.1172/jci.insight.168437 · Cited by 15
Ambegaonkar, A. A., Holla, P., Sohn, H., George, R. M., Tran, T. M., & Pierce, S. K. (2024) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2313672121 · Cited by 15
Garritsen, A., Scholzen, A., van den Nieuwenhof, D. W. A., Smits, A. P. F., Datema, E. S., van Galen, L. S., & Kouwijzer, M. (2021) · Scandinavian Journal of Infectious Diseases · doi:10.1080/23744235.2021.1893378 · Cited by 15
Comparative analysis of antibodies to SARS-CoV-2 between asymptomatic and convalescent patients
Dwyer, C. J., Cloud, C. A., Wang, C., Heidt, P., Chakraborty, P., Duke, T., McGue, S. R., Jeffcoat, B., Dunne, J., Johnson, L., et al. (2021) · iScience · doi:10.1016/j.isci.2021.102489 · Cited by 15
Lyski, Z. L., Brunton, A. E., Strnad, M., Sullivan, P. E., Siegel, S. A. R., Tafesse, F., Slifka, M. K., & Messer, W. B. (2021) · The Journal of Infectious Diseases · doi:10.1093/infdis/jiab585 · Cited by 16
SARS-CoV-2-specific CD4+ T cell longevity correlates with Th17-like phenotype
Terahara, K., Sato, T., Adachi, Y., Tonouchi, K., Onodera, T., Moriyama, S., Sun, L., Takano, T., Nishiyama, A., Kawana‐Tachikawa, A., et al. (2022) · iScience · doi:10.1016/j.isci.2022.104959 · Cited by 15
New insights into human immune memory from SARS‐CoV ‐2 infection and vaccination
Hartley, G. E., Edwards, E. S. J., O’Hehir, R. E., & van Zelm, M. C. (2022) · Allergy · doi:10.1111/all.15502 · Cited by 15
Serial SARS-CoV-2 Receptor-Binding Domain Antibody Responses in Patients Receiving Dialysis
Anand, S., Montez‐Rath, M. E., Han, J., García, P., Cadden, L., Hunsader, P., KERSCHMANN, R. L., Beyer, P., Boyd, S. D., Chertow, G. M., et al. (2021) · Annals of Internal Medicine · doi:10.7326/m21-0256 · Cited by 14
da Silveira, M. F., Mesenburg, M. A., Dellagostin, O. A., de Oliveira, N. R., Maia, M. A. C., Santos, F. D. S., Vale, A. M., Menezes, A. M. B., Victora, G. D., Victora, C. G., et al. (2021) · The Brazilian Journal of Infectious Diseases · doi:10.1016/j.bjid.2021.101601 · Cited by 14
Noto, A., Joo, V., Mancarella, A., Suffiotti, M., Pellaton, C., Fenwick, C. W., Perreau, M., & Pantaleo, G. (2022) · Viruses · doi:10.3390/v14122665 · Cited by 14
Fryer, H. A., Hartley, G. E., Edwards, E. S. J., Varese, N. P., Boo, I., Bornheimer, S. J., Hogarth, P. M., Drummer, H. E., O’Hehir, R. E., & van Zelm, M. C. (2023) · Journal of Clinical Immunology · doi:10.1007/s10875-023-01527-2 · Cited by 14
A mathematical model for the within-host (re)infection dynamics of SARS-CoV-2
Schuh, L., Markov, P. V., Veliov, V. M., & Stilianakis, N. I. (2024) · Mathematical Biosciences · doi:10.1016/j.mbs.2024.109178 · Cited by 14
Bubonja‐Šonje, M., Batičić, L., Abram, M., & Grbeša, Đ. C. (2021) · Journal of Virological Methods · doi:10.1016/j.jviromet.2021.114173 · Cited by 14
Immunology of SARS-CoV-2 infections and vaccines
Schenten, D., & Bhattacharya, D. (2021) · Advances in immunology · doi:10.1016/bs.ai.2021.08.002 · Cited by 14
Murugesan, K., Jagannathan, P., Altamirano, J., Maldonado, Y., Bonilla, H. F., Jacobson, K. B., Parsonnet, J., Andrews, J. R., Shi, R., Boyd, S. D., et al. (2022) · Clinical Infectious Diseases · doi:10.1093/cid/ciac045 · Cited by 14
COVID-19 in the Immunocompromised Host, Including People with Human Immunodeficiency Virus
Jakharia, N., Subramanian, A. K., & Shapiro, A. E. (2022) · Infectious Disease Clinics of North America · doi:10.1016/j.idc.2022.01.006 · Cited by 15
Shin, J. J., Par‐Young, J., Ünlü, S., McNamara, A., Park, H., Shin, M. S., Gee, R. J., Doyle, H. A., Afinogenova, Y., Zidan, E., et al. (2022) · Journal of Clinical Immunology · doi:10.1007/s10875-022-01296-4 · Cited by 14
6-month SARS-CoV-2 antibody persistency in a Tyrolian COVID-19 cohort
Deisenhammer, F., Borena, W., Bauer, A., Kimpel, J., Rudzki, D., Schanda, K., Egeter, J., Hüfner, K., Sperner‐Unterweger, B., & Reindl, M. (2020) · Wiener klinische Wochenschrift · doi:10.1007/s00508-020-01795-7 · Cited by 13
Bal, A., Trabaud, M., Fassier, J., Rabilloud, M., Saker, K., Langlois, C., Guibert, N., Paul, A., Alfaiate, D., Massardier-Pilonchery, A., et al. (2021) · Clinical Microbiology and Infection · doi:10.1016/j.cmi.2021.01.003 · Cited by 13
Adamec, I., Rogić, D., Penz, M.-G., Braun, C., & Habek, M. (2021) · Journal of Neuroimmunology · doi:10.1016/j.jneuroim.2021.577788 · Cited by 13
T and B cell responses in different immunization scenarios for COVID-19: a narrative review
Mortari, E. P., Ferrucci, F., Zografaki, I., Carsetti, R., & Pacelli, L. (2025) · Frontiers in Immunology · doi:10.3389/fimmu.2025.1535014 · Cited by 14
Persistent COVID-19 Symptoms Minimally Impact the Development of SARS-CoV-2-Specific T Cell Immunity
Fang, H., Wegman, A. D., Ripich, K., Friberg, H., Currier, J. R., Thomas, S. J., Endy, T. P., & Waickman, A. T. (2021) · Viruses · doi:10.3390/v13050916 · Cited by 13
Reiners, N., Schnurra, C., Trawinski, H., Kannenberg, J., Hermsdorf, T., Aebischer, A., Schöneberg, T., Reiche, S., & Jassoy, C. (2021) · European Journal of Clinical Microbiology & Infectious Diseases · doi:10.1007/s10096-021-04284-5 · Cited by 13
Kealy, L. C., & Good‐Jacobson, K. L. (2021) · Oxford Open Immunology · doi:10.1093/oxfimm/iqab018 · Cited by 14
Evaluation of Clinical and Immune Responses in Recovered Children with Mild COVID-19
Tian, X., Bai, Z., Cao, Y., Liu, H., Liu, D., Liu, W., & Li, J. (2022) · Viruses · doi:10.3390/v14010085 · Cited by 13
Immune durability and protection against SARS-CoV-2 re-infection in Syrian hamsters
Field, C. J., Heinly, T. A., Patel, D., Sim, D. G., Luley, E., Gupta, S. L., Vanderford, T. H., Wrammert, J., & Sutton, T. C. (2022) · Emerging Microbes & Infections · doi:10.1080/22221751.2022.2058419 · Cited by 13
The Kinetics of COVID-19 Vaccine Response in a Community-Vaccinated Population
Tu, M. K., Chiang, S. H., Bender, R. A., Wong, D. T., & Strom, C. M. (2022) · The Journal of Immunology · doi:10.4049/jimmunol.2100919 · Cited by 14
Beliakova‐Bethell, N., Maruthai, K., Xu, R., Salvador, L. C. M., & Garg, A. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.894543 · Cited by 14
Ferrari, L., Favero, C., Solazzo, G., Mariani, J., Luganini, A., Ferraroni, M., Montomoli, E., Milani, G. P., & Bollati, V. (2022) · Frontiers in Cellular and Infection Microbiology · doi:10.3389/fcimb.2022.882302 · Cited by 13
Azamor, T., Horbach, I. S., Cunha, D. B. E., Melgaço, J. G., da Silva, A. M. V., Tubarão, L. N., Azevedo, A. D. S., Santos, R. T., Alves, N. D. S., Machado, T. L., et al. (2022) · Viruses · doi:10.3390/v14091916 · Cited by 14
Pernet, O., Balog, S., Kawaguchi, E. S., Lam, C. N., Anthony, P., Simon, P. A., Kotha, R., Sood, N., Hu, H., & Kovács, A. (2023) · Microbiology Spectrum · doi:10.1128/spectrum.03709-22 · Cited by 13
Klebanoff, S. D., Rodda, L. B., Morishima, C., Wener, M. H., Yuzefpolskiy, Y., Bettelli, E., Buckner, J. H., Speake, C., Pepper, M., & Campbell, D. (2023) · JCI Insight · doi:10.1172/jci.insight.168663 · Cited by 13
Self-citationFtouh, M., Kalboussi, N., Abid, N., Sfar, S., Mignet, N., & Bahloul, B. (2021) · PPAR Research · doi:10.1155/2021/6741290 · Cited by 13
COVID-19 – pathogenesis and immunological findings across the clinical manifestation spectrum
Carsetti, R., Quinti, I., & Locatelli, F. (2021) · Current Opinion in Pulmonary Medicine · doi:10.1097/mcp.0000000000000775 · Cited by 12
Humoral response to SARS-CoV-2 infection among liver transplant recipients
Becchetti, C., Broekhoven, A. G. C., Dahlqvist, G., Fraga, M., Zambelli, M. F., Ciccarelli, O., Saouli, A.-C., Trizzino, A., Banz, V. M., Dufour, J., et al. (2022) · Gut · doi:10.1136/gutjnl-2021-326609 · Cited by 12
Augello, M., Bono, V., Rovito, R., Tincati, C., Monforte, A. D., & Marchetti, G. C. (2023) · AIDS · doi:10.1097/qad.0000000000003585 · Cited by 12
IFN-λ uniquely promotes CD8 T cell immunity against SARS-CoV-2 relative to type I IFN
Solstad, A., Denz, P. J., Kenney, A. D., Mahfooz, N. S., Speaks, S., Gong, Q., Robinson, R., Long, M. E., Forero, A., Yount, J. S., et al. (2024) · JCI Insight · doi:10.1172/jci.insight.171830 · Cited by 13
Self-citationFryer, H. A., Geers, D., Gommers, L., Zaeck, L. M., Tan, N. H., Jones, B., Goorhuis, A., Postma, D. F., Visser, L. G., Hogarth, P. M., et al. (2024) · Journal of Infection · doi:10.1016/j.jinf.2024.106246 · Cited by 13
Decrypting the Immune Symphony for RNA Vaccines
Weidensee, B., & Sahu, I. (2025) · Vaccines · doi:10.3390/vaccines13080882 · Cited by 13
Melotti, R., Scaggiante, F., Falciani, M., Weichenberger, C. X., Foco, L., Lombardo, S., Grandi, A. D., von Laer, D., Mahlknecht, A., Pramstaller, P. P., et al. (2021) · Epidemiology and Infection · doi:10.1017/s0950268821001886 · Cited by 13
Neagu, M. T., Constantin, C., & Surcel, M. (2021) · International Journal of Environmental Research and Public Health · doi:10.3390/ijerph182413173 · Cited by 12
pcMSC Modulates Immune Dysregulation in Patients With COVID-19-Induced Refractory Acute Lung Injury
Chen, M.-C., Lai, K. S.-L., Chien, K.-L., Teng, S.-T., Lin, Y.-R., Chao, W., Lee, M.-J., Wei, P., Huang, Y., Kuo, H., et al. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.871828 · Cited by 12
Jiménez, D., & Arias, M. T. (2022) · Immunological Medicine · doi:10.1080/25785826.2022.2066251 · Cited by 12
Serwanga, J., Baine, C., Mugaba, S., Ankunda, V., Auma, B. O., Oluka, G. K., Kato, L., Kitabye, I., Sembera, J., Odoch, G., et al. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1183983 · Cited by 12
Khanolkar, A. (2021) · Cells · doi:10.3390/cells11010067 · Cited by 12
Maturation of SARS-CoV-2 Spike-specific memory B cells drives resilience to viral escape
Marzi, R., Bassi, J., Silacci-Fregni, C., Bartha, I., Muoio, F., Culap, K., Sprugasci, N., Lombardo, G., Saliba, C., Cameroni, E., et al. (2022) · iScience · doi:10.1016/j.isci.2022.105726 · Cited by 12
SARS-CoV-2 Portrayed against HIV: Contrary Viral Strategies in Similar Disguise
Duerr, R., Crosse, K. M., Valero-Jimenez, A. M., & Dittmann, M. (2021) · Microorganisms · doi:10.3390/microorganisms9071389 · Cited by 12
Past SARS-CoV-2 infection elicits a strong immune response after a single vaccine dosePreprint
Chahla, R. E., Tomas‐Grau, R. H., Cazorla, S. I., Ploper, D., Pingitore, E. V., López, M. A., Aznar, P., Alcorta, M., Vélez, E. M. D. M., Stagnetto, A., et al. (2021) · medRxiv · doi:10.1101/2021.03.14.21253039 · Cited by 12
Durability of the humoral immune response in recovered COVID-19 patients
Mahallawi, W. H., Alzahrani, M. E., & Alahmadey, Z. Z. (2021) · Saudi Journal of Biological Sciences · doi:10.1016/j.sjbs.2021.02.011 · Cited by 11
Adaptive immune responses to SARS-CoV-2
Forthal, D. N. (2021) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2021.02.009 · Cited by 11
The COVID‐19 pandemic: key considerations for the epidemic and its control
Ørskov, S., Nielsen, B. F., Føns, S., Sneppen, K., & Simonsen, L. (2021) · Apmis · doi:10.1111/apm.13141 · Cited by 12
Seck, S. M., Mbow, M., Kane, Y., Cissé, M. M., Faye, G., Kama, A., Sarr, M., Nitcheu, P., Dahaba, M., Diallo, I. M., et al. (2021) · BMC Nephrology · doi:10.1186/s12882-021-02582-w · Cited by 11
Kittikraisak, W., Hunsawong, T., Punjasamanvong, S., Wongrapee, T., Suttha, P., Piyaraj, P., Leepiyasakulchai, C., Tanathitikorn, C., Yoocharoen, P., Jones, A. R., et al. (2021) · Influenza and Other Respiratory Viruses · doi:10.1111/irv.12975 · Cited by 11
Kowalski, E., Stengel, A., Schneider, A., Goebel‐Stengel, M., Zipfel, S., & Graf, J. (2022) · Vaccines · doi:10.3390/vaccines10030455 · Cited by 11
Yuzefpolskiy, Y., Morawski, P. A., Fahning, M. L., Speake, C., Lord, S. M., Chaudhary, A., Morishima, C., Wener, M. H., Kita, M., McCarthy, L. H., et al. (2022) · The Journal of Immunology · doi:10.4049/jimmunol.2101142 · Cited by 11
Self-citationValidation of Ligand Tetramers for the Detection of Antigen-Specific Lymphocytes
Fitzpatrick, K. S., Degefu, H. N., Poljakov, K., Bibby, M. G., Remington, A. J., Searles, T. G., Gray, M. D., Boonyaratanakornkit, J. B., Rosato, P. C., & Taylor, J. J. (2023) · The Journal of Immunology · doi:10.4049/jimmunol.2200934 · Cited by 12
Radion, E. I., Mukhin, V. E., Kholodova, A. V., Vladimirov, I. S., Alsaeva, D. Y., Zhdanova, A. S., Ulasova, N. Y., Bulanova, N. V., Makarov, V. V., Keskinov, A. A., et al. (2023) · Viruses · doi:10.3390/v15061349 · Cited by 11
Considerations for Choosing T Cell Assays during a Pandemic
Law, J. C., & Watts, T. H. (2023) · The Journal of Immunology · doi:10.4049/jimmunol.2300129 · Cited by 11
Limoges, M.-A., Quenum, A., Chowdhury, M. M. H., Rexhepi, F., Namvarpour, M., Akbari, S. A., Rioux‐Perreault, C., Nandi, M., Lucier, J., Lemaire‐Paquette, S., et al. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1223936 · Cited by 14
Potent and Persistent Antibody Response in COVID-19 Recovered Patients
Tian, X., Liu, L., Jiang, W.-G., Zhang, H., Liu, W., & Li, J. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.659041 · Cited by 11
Cutaneous Pathology of COVID-19 as a Window into Immunologic Mechanisms of Disease
Gallman, A. E., & Fassett, M. S. (2021) · Dermatologic Clinics · doi:10.1016/j.det.2021.05.008 · Cited by 11
Li, H., Lin, H., Chen, X., Li, H., Li, H., Lin, S., Huang, L., Chen, G., Zheng, G., Wang, S., et al. (2022) · Frontiers in Cellular and Infection Microbiology · doi:10.3389/fcimb.2022.814782 · Cited by 13
Guo, Y., Guo, Y., Zhang, Y., Li, F., Yu, J., Zhang, Y., Shen, Z., Mao, R., Zhu, H., & Zhang, J. (2023) · Journal of Medical Virology · doi:10.1002/jmv.28550 · Cited by 10
Al‐Rifai, R. H., Hosani, F. I. A., Abuyadek, R. M., Atef, S. H., Donnelly, J. G., Leinberger‐Jabari, A., Ahmed, L. A., Altrabulsi, B., Alatoom, A. A., Alsuwaidi, A. R., et al. (2023) · Frontiers in Medicine · doi:10.3389/fmed.2022.1092646 · Cited by 10
Abdelaziz, M. O., Raftery, M. J., Weihs, J., Bielawski, O., Edel, R., Köppke, J. K. C., Vladimirova, D., Adler, J. M., Firsching, T. C., Voß, A., et al. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1166765 · Cited by 10
Detection of SARS‐CoV‐2‐specific memory B cells to delineate long‐term COVID‐19 immunity
Thieme, C. J., Abou‐El‐Enein, M., Fritsche, E., Anft, M., Paniskaki, K., Skrzypczyk, S., Doevelaar, A., Elsallab, M., Brindle, N. R., Blazquez‐Navarro, A., et al. (2021) · Allergy · doi:10.1111/all.14827 · Cited by 10
Sulbarán, G., Maisonnasse, P., Amen, A., Effantin, G., Guilligay, D., Dereuddre‐Bosquet, N., Burger, J. A., Poniman, M., Grobben, M., Buisson, M., et al. (2022) · Cell Reports Medicine · doi:10.1016/j.xcrm.2022.100528 · Cited by 11
INFERRED RESOLUTION THROUGH HERD IMMMUNITY OF FIRST COVID-19 WAVE IN MANAUS, BRAZILIAN AMAZONPreprint
Prowse, T. A. A., Purcell, T., Baía-da-Silva, D. C., Sampaio, V. D. S., Monteiro, W. M., Wood, J., Müeller, I., McVernon, J., Lacerda, M., & Ross, J. V. (2020) · medRxiv · doi:10.1101/2020.09.25.20201939 · Cited by 10
Characterization of humoral and SARS-CoV-2 specific T cell responses in people living with HIVPreprint
Alrubayyi, A., Gea‐Mallorquí, E., Touizer, E., Hameiri‐Bowen, D., Kopycinski, J. T., Charlton, B. G., Fisher-Pearson, N., Muir, L., Rosa, A., Roustan, C., et al. (2021) · Research Square · doi:10.21203/rs.3.rs-309746/v1 · Cited by 12
Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Immunity and Reinfection
Dan, J. M., & Mehta, S. R. (2021) · Clinical Infectious Diseases · doi:10.1093/cid/ciaa1936 · Cited by 9
Damluji, A. A., Christenson, R. H., & deFilippi, C. R. (2021) · Journal of the American Heart Association · doi:10.1161/jaha.120.019506 · Cited by 9
Study of humoral and cellular immunity in vaccinated with mRNA‐1273
Gutiérrez‐Bautista, J. F., López‐Nevot, M. Á., Gómez-Vicente, E., Quesada, T., Marín, E. M., Rodríguez, A. I. E., Rodríguez, A. I. E., Rodríguez‐Granger, J., Cobo, F., & Sampedro, A. (2022) · Apmis · doi:10.1111/apm.13215 · Cited by 10
Vitiello, L., Gatta, L., Ilari, S., Bonassi, S., Cristina, M., Ciatti, F., Fini, M., Proietti, S., Russo, P., Tomino, C., et al. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.836495 · Cited by 10
Characteristics and Roles of T Follicular Helper Cells in SARS-CoV-2 Vaccine Response
Chi, X., Gu, J., & Ma, X. (2022) · Vaccines · doi:10.3390/vaccines10101623 · Cited by 9
Gillot, C., Favresse, J., David, C., Maloteau, V., Dogné, J., & Douxfils, J. (2024) · Microbiology Research · doi:10.3390/microbiolres15010028 · Cited by 9
An EKF prediction of COVID-19 propagation under vaccinations and viral variants
Zhu, X., Shi, Y., & Zhong, Y. (2024) · Mathematics and Computers in Simulation · doi:10.1016/j.matcom.2024.12.012 · Cited by 9
Adaptive immune responses to SARS-CoV-2 in recovered severe COVID-19 patients
Olea, B., Albert, E., Torres, I., Amat, P., Remigia, M. J., Gozalbo‐Rovira, R., Rodríguez‐Díaz, J., Buesa, J., Blasco, M. L., Redón, J., et al. (2021) · Journal of Clinical Virology · doi:10.1016/j.jcv.2021.104943 · Cited by 9
Dynamics of SARS-CoV-2-specific antibodies among COVID19 biobank donors in Argentina
Longueira, Y., Polo, M. L., InViV working group, Turk, G., Laufer, N., & Biobanco de Enfermedades Infecciosas Colección COVID19 working group (2021) · Heliyon · doi:10.1016/j.heliyon.2021.e08140 · Cited by 10
Facciuolo, A., Scruten, E., Lipsit, S., Lang, A. L. S., Cates, Z. P., Lew, J. M., Falzarano, D., Gerdts, V., KUSALIK, A. J., & Napper, S. (2022) · Scientific Reports · doi:10.1038/s41598-022-12032-8 · Cited by 9
Huang, R., Ying, L., Wang, J., Xia, J. L., Zhang, Y., Mao, H., Zhang, R., Zang, R., Le, Z., Shu, Q., et al. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1139620 · Cited by 9
Benchmarking SARS CoV-2 Infection in the Workplace to Support Continuity of Operations
Iddins, B. O., Waugh, M. H., Buck, B., Cato, T., Graham, D. E., Attia, K., Jones, D. R., Partin, A. M., Shourbaji, R., & Wesh, C. (2021) · Journal of Occupational and Environmental Medicine · doi:10.1097/jom.0000000000002188 · Cited by 9
Cutting Edge: SARS-CoV-2 Infection Induces Robust Germinal Center Activity in the Human Tonsil
Tan, H., Wragg, K. M., Kelly, H. G., Esterbauer, R., Dixon, B. J., Lau, J. S. Y., Flanagan, K. L., van de Sandt, C. E., Kedzierska, K., McMahon, J. H., et al. (2022) · The Journal of Immunology · doi:10.4049/jimmunol.2101199 · Cited by 9
Perugino, C. A., Liu, H., Feldman, J. E., Hauser, B. M., Jacob-Dolan, C., Nathan, A., Zhou, Z., Kaseke, C., Tano-Menka, R., Getz, M. A., et al. (2022) · medRxiv · doi:10.1101/2021.12.30.21268554 · Cited by 9
Kardava, L., Lim, J., Buckner, C. M., de Assis, F. L., Zhang, X., Wang, W. J., Melnyk, M. L. S., Merhebi, O. E., Trihemasava, K., Teng, I., et al. (2025) · Cell Reports · doi:10.1016/j.celrep.2025.115557 · Cited by 8
A Minimalist Strategy Towards Temporarily Defining Protection for COVID-19
Cimolai, N. (2020) · SN Comprehensive Clinical Medicine · doi:10.1007/s42399-020-00533-4 · Cited by 8
Lledó, A., Retuerto, M., Almendro-Vázquez, P., Fernández‐Ruiz, M., Galindo-Izquierdo, M., Laguna‐Goya, R., Paz‐Artal, E., Lalueza, A., Aguado, J. M., & Pablos, J. L. (2021) · Seminars in Arthritis and Rheumatism · doi:10.1016/j.semarthrit.2021.10.006 · Cited by 8
Kilpeläinen, A., Jiménez‐Moyano, E., Blanch-Lombarte, O., Ouchi, D., Peña, R., Quirant‐Sánchez, B., Pérez‐Caballero, R., Chamorro, A., Blanco, I., Martínez-Cáceres, E. M., et al. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.815041 · Cited by 9
Bisceglia, H., Barrier, J., Ruiz, J., & Pagnon, A. (2023) · Journal of Immunological Methods · doi:10.1016/j.jim.2023.113457 · Cited by 8
To, A., Wong, T. A. S., Lieberman, M. M., Thompson, K. S., Ball, A. H., Pessaint, L., Greenhouse, J. J., Daham, N., Cook, A., Narvaez, B., et al. (2022) · ACS Infectious Diseases · doi:10.1021/acsinfecdis.1c00600 · Cited by 8
Chang, C., Vlad, G., Vasilescu, E. R., Li, P., Husain, S. A., Silvia, E. A., Cohen, D. J., Ratner, L. E., Sun, W., Mohan, S., et al. (2022) · Clinical & Translational Immunology · doi:10.1002/cti2.1411 · Cited by 8
Akhtar, M., Basher, S. R., Nizam, N. N., Kamruzzaman, M., Khaton, F., Banna, H. A., Kaisar, M. H., Karmakar, P. C., Hakim, A., Akter, A., et al. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.1052374 · Cited by 8
Diego, J. G.-B., Singh, G., Jangra, S., Handrejk, K., Laporte, M., Chang, L. A., Zahed, S. S. E., Pache, L., Chang, M. W., Warang, P., et al. (2024) · PLoS Pathogens · doi:10.1371/journal.ppat.1011805 · Cited by 8
Gallichotte, E. N., Nehring, M., Young, M. C., Pugh, S., Sexton, N. R., Fitzmeyer, E. A., Quicke, K. M., Richardson, M., Pabilonia, K. L., Ehrhart, N. P., et al. (2021) · Microbiology Spectrum · doi:10.1128/spectrum.00224-21 · Cited by 8
Federico, M. (2022) · Journal of Immunology Research · doi:10.1155/2022/4028577 · Cited by 9
Longitudinal kinetics of RBD+ antibodies in COVID-19 recovered patients over 14 months
Eyran, T., Vaisman‐Mentesh, A., Taussig, D., Dror, Y., Aizik, L., Kigel, A., Rosenstein, S., Bahar, Y., Ini, D., Tur‐Kaspa, R., et al. (2022) · PLoS Pathogens · doi:10.1371/journal.ppat.1010569 · Cited by 8
Chi, H., Zhou, K., Shen, L., Xu, J., Li, J., Chen, S., Wu, X., Tung, T., Shen, B., & Zhu, H. (2022) · International Immunopharmacology · doi:10.1016/j.intimp.2022.109019 · Cited by 8
Metadata
- Authors
- Rodda, L. B., Netland, J., Shehata, L., Pruner, K. B., Morawski, P. A., Thouvenel, C. D., Takehara, K. K., Eggenberger, J., Hemann, E. A., Waterman, H. R., Fahning, M. L., Chen, Y., Hale, M., Rathe, J., Stokes, C., Wrenn, S., Fiala, B., Carter, L., Hamerman, J. A., King, N. P., Gale, M., Campbell, D. J., Rawlings, D. J., & Pepper, M.
- Affiliations
- University of Washington (US)
- Benaroya Research Institute (US)
- Corresponding author
- Pepper, Marion
- ORCID
- Rodda, Lauren B.
- Netland, Jason
- Shehata, Laila
- Pruner, Kurt B.
- Morawski, Peter A.
- Thouvenel, Christopher D.
- Takehara, Kennidy K.
- Eggenberger, Julie
- Hemann, Emily A.
- Waterman, Hayley R.
- Fahning, Mitchell L.
- Chen, Yu
- Hale, Malika
- Stokes, Caleb
- Wrenn, Samuel
- Fiala, Brooke
- Carter, Lauren
- Hamerman, Jessica A.
- King, Neil P.
- Gale, Michael
- Campbell, Daniel J.
- Rawlings, David J.
- Pepper, Marion
- Venue
- Cell
- Publisher
- Elsevier BV
- Published
- 2021-01
- Volume
- 184
- Issue
- 1
- Pages
- 169-183.e17
- ISSN
- 0092-8674 (ISSN-L)
- PMC
- PMC7682481
- OpenAlex
- W3107730772
- Cited by
- 647
- References
- 80
- Citations by year
- 2026: 10 · 2025: 30 · 2024: 46 · 2023: 85 · 2022: 171 · 2021: 278
- FWCI
- 18.44
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Licence
- Locations
- Cell (publishedVersion)
- medRxiv (acceptedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- PubMed Central (submittedVersion)
- Funders
- National Institutes of Health
- Burroughs Wellcome Fund
- Topics
- Health Sciences › Medicine › Infectious Diseases › SARS-CoV-2 and COVID-19 Research
- Life Sciences › Immunology and Microbiology › Immunology › Immune responses and vaccinations
- Health Sciences › Medicine › Infectious Diseases › COVID-19 Clinical Research Studies
- Keywords
- SARS-CoV-2, COVID-19 pandemic, mild COVID-19, immunological memory, memory B cells, memory T cells, neutralizing antibodies, IgG, long-term immunity, cytokine production, monoclonal antibodies, antiviral immunity
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
